Research peptides in sarcopenia: myostatin, GH-axis, and mitochondrial approaches
Reviewed by the BestHealingPeptides Editorial Team ·
Sarcopenia — age-related loss of skeletal muscle mass and function — affects an estimated 5-13% of adults aged 60-70 and 11-50% of adults over 80, contributing substantially to falls, disability, and mortality in older populations. Pharmacological approaches to sarcopenia remain limited relative to the disease burden, with resistance exercise and adequate protein intake as the mainstay interventions. Peptide research spans three complementary approaches: myostatin-pathway inhibition (follistatin and related compounds), IGF-1/protein synthesis stimulation (IGF-1 LR3), and mitochondrial/exercise-mimetic pharmacology (MOTS-c, tesamorelin GH-axis). Clinical translation across these approaches has been challenging, with functional-endpoint requirements proving difficult to meet consistently.
The recurring pattern across myostatin-pathway clinical development (ACE-083 follistatin-Fc, bimagrumab, and related programmes) has been that anatomical muscle hypertrophy is achievable but the translation to consistent functional-endpoint improvement is challenging — reflecting the multi-factorial nature of muscle function in older and disease populations. This translation-gap remains one of the key open questions in sarcopenia pharmacology and informs continued research on combined pharmacological-plus-exercise-intervention strategies.
— Notable finding
Condition background
Sarcopenia is defined by low muscle mass combined with low muscle strength or low physical performance according to consensus criteria (EWGSOP2 in Europe). The condition progresses through age-related mechanisms including reduced satellite cell activity, mitochondrial dysfunction, chronic low-grade inflammation, altered neuromuscular junction function, anabolic resistance (reduced protein-synthetic response to amino acid intake), and reduced physical activity. Consequences include reduced functional capacity, increased falls risk, hospitalisation-associated immobility complications, and increased mortality. Sarcopenic obesity — combining muscle loss with excess adiposity — is a particularly disabling phenotype in older populations. The pharmacological space has historically been small; recent progress in myostatin-pathway pharmacology and metabolic-peptide research has begun to expand the therapeutic toolkit.
Current treatment landscape
Current UK management of sarcopenia is primarily non-pharmacological. Resistance exercise (specifically progressive resistance training) is the highest-efficacy intervention documented for muscle mass and function preservation in older populations, with NHS physiotherapy and community exercise programmes providing access. Adequate protein intake (typically 1.0-1.2 g/kg/day in older adults, higher in acute illness contexts) supports the anabolic response to exercise. Vitamin D supplementation is recommended where deficient. Management of comorbidities that impair mobility and nutrition is important. No pharmacological medication is currently licensed by MHRA specifically for sarcopenia. Off-label use of testosterone in hypogonadal older men is documented in specialist-endocrinology settings with modest muscle-preservation effects. GH replacement in confirmed GH deficiency is a specialist-endocrinology consideration. Bariatric-surgery-associated sarcopenia is a specific clinical scenario receiving increasing pharmacological research attention.
Why peptides are studied here
Three complementary pharmacological approaches to sarcopenia research are represented in the peptide space. The myostatin-inhibition approach exploits the observation that myostatin (GDF-8) is the dominant endogenous negative regulator of muscle mass — myostatin blockade increases muscle mass in animal models and human muscular-dystrophy trials. [Follistatin](/peptides/follistatin) binds and sequesters myostatin (and related TGF-β family ligands), providing pharmacological muscle-hypertrophy potential; ACE-083 (follistatin-Fc fusion) progressed through Phase II trials in Duchenne muscular dystrophy and FSHD with mixed results. The IGF-1/protein-synthesis approach uses [IGF-1 LR3](/peptides/igf-1-lr3) — a recombinant IGF-1 analogue with extended half-life — to drive IGF-1R-mediated satellite cell activation and myoblast proliferation; grey-market IGF-1 LR3 use in strength-sport communities has documented substantial (though safety-uncharacterised) muscle-hypertrophy effects. The mitochondrial/exercise-mimetic approach engages [MOTS-c](/peptides/mots-c) — a mitochondrial-derived peptide activating AMPK with exercise-mimetic effects on muscle endurance and metabolic function. The GH-axis approach uses [tesamorelin](/peptides/tesamorelin), a GHRH analogue driving endogenous GH release with downstream IGF-1 elevation; tesamorelin is FDA-licensed for HIV-associated lipodystrophy rather than sarcopenia specifically but the mechanistic overlap is relevant. Clinical translation across all these approaches has been challenging, with functional-endpoint requirements (six-minute walk, timed function tests) proving difficult to meet consistently despite anatomical hypertrophy.
Relevant research peptides
Follistatin
A secreted glycoprotein originally isolated from ovarian follicular fluid as an inhibitor of follicle-stimulating hormone (FSH) secretion — the origin of the name. Subsequently characterised as a high-affinity inhibitor of members of the transforming growth factor beta (TGF-β) superfamily, particularly myostatin (GDF-8) and activin. The myostatin-inhibitor mechanism has driven substantial research interest in skeletal-muscle applications including Duchenne muscular dystrophy and sarcopenia. Not licensed as a medicine.
IGF-1 LR3
A recombinant analogue of human insulin-like growth factor 1 (IGF-1) with two engineering modifications: N-terminal 13-amino-acid extension (giving the 'Long' designation) and glutamate-to-arginine substitution at position 3 (the 'R3' designation). Both modifications reduce affinity for IGF-binding proteins (IGFBPs), leaving more free unbound IGF-1 available for IGF-1R receptor binding and consequently substantially extending biological half-life versus native IGF-1. Widely used in cell culture research; not licensed as a medicine.
MOTS-c
A 16-amino-acid mitochondrial-derived peptide (MDP) encoded within the mitochondrial 12S rRNA region of the mitochondrial genome — the first MDP discovered with established metabolic-regulatory function. MOTS-c modulates AMPK signalling and folate cycle methylation, with pre-clinical evidence for effects on insulin sensitivity, exercise capacity, and skeletal-muscle glucose handling. Cross-listed in the metabolic and longevity clusters; not licensed in any jurisdiction.
Tesamorelin
A stabilised analogue of full-length human GHRH (1-44) with a trans-3-hexenoyl group attached to the N-terminal tyrosine, conferring protease resistance against DPP-4. The only GHRH-analogue compound to hold current FDA approval — licensed as Egrifta (marketed by Theratechnologies) for HIV-associated lipodystrophy. Distinguished from sermorelin and CJC-1295 by its retained full 44-amino-acid sequence rather than the 1-29 truncation.
Sermorelin
The first 29 amino acids of native human GHRH — the biologically active N-terminal fragment retaining full GHRH-receptor agonism. The prototype GHRH analogue; formerly licensed as Geref by Serono for paediatric growth-hormone deficiency diagnostic testing. Short half-life (~5-12 minutes) and pulsatile-preserving GH-release pattern make it the classical GH-axis research probe.
Notable study findings
Follistatin (ACE-083 Phase II)
ACE-083 (follistatin-Fc fusion) achieved intramuscular hypertrophy in Phase II trials for Duchenne muscular dystrophy and FSHD but functional endpoints (six-minute walk, timed function tests) did not consistently reach registrable improvement thresholds. Development did not progress to Phase III — a recurring theme across myostatin-axis clinical translation.
IGF-1 LR3 (pre-clinical)
Pre-clinical satellite-cell activation and myoblast-proliferation studies with IGF-1 LR3 demonstrate the compound's mechanistic capacity to drive muscle protein synthesis through IRS-1/PI3K/Akt signalling. Clinical characterisation in sarcopenia specifically is limited; grey-market use in strength-sport communities has documented substantial hypertrophy effects with substantial safety uncertainty.
MOTS-c (exercise-mimetic)
MOTS-c administration in aged mice produces AMPK activation, improved muscle endurance, and improved metabolic flexibility — supporting the mitochondrial-peptide exercise-mimetic framework potentially relevant to sarcopenia, though clinical characterisation in aged human populations remains limited.
Bimagrumab (comparative)
Bimagrumab (a myostatin-antibody rather than follistatin-derived compound) explored the same mechanistic space through Phase III sarcopenia development with mixed results; the compound was subsequently repositioned for obesity development. The bimagrumab clinical trajectory illustrates the challenge of defining registrable sarcopenia endpoints across the myostatin-pathway class.
UK regulatory notes
None of the peptides referenced on this page are MHRA-licensed for sarcopenia. Follistatin, IGF-1 LR3, and MOTS-c are research compounds not licensed as medicines in any jurisdiction. Tesamorelin (Egrifta) is FDA-licensed for HIV-associated lipodystrophy but not sarcopenia; MHRA licensing is limited. All these compounds fall within WADA's S2 category (Peptide Hormones, Growth Factors, Related Substances and Mimetics) — MOTS-c specifically was added to the Prohibited List following characterisation of exercise-endurance effects. Research use in appropriate laboratory contexts is not restricted by UK medicines law; supply for human use engages the Human Medicines Regulations 2012.
Frequently asked questions
What is sarcopenia?
Why is exercise still the mainstay treatment despite pharmacological research progress?
Why has myostatin-pathway pharmacology not delivered licensed sarcopenia medications yet?
Is IGF-1 LR3 a viable sarcopenia treatment?
How does MOTS-c differ from other sarcopenia-relevant peptides?
Is there any licensed pharmacological treatment for sarcopenia in the UK?
What is sarcopenic obesity?
Where to source research peptides for laboratory research
The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.
- PeptideAuthority.co.uk
UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.
- PeptideBarn.co.uk
Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.